Onderzoeker
Mourad Gumusboga
Affiliaties
- Mycobacteriologie (Onderzoekseenheid)
Lid
Vanaf1 jan 2003 → Heden - Mycobacteriologie (Onderzoekseenheid)
Lid
Vanaf31 dec 2002 → 16 apr 2015
Projecten
1 - 2 of 2
- Novel High-Dose Tuberculosis Retreatment Regimens: How to overcome resistance without Creating MoreVanaf1 okt 2018 → Heden
- Institutional strengthening of the Mycobacteria Reference Laboratory (LRM, Bénin) for quality services and better quality of health care for Mycobacteria and other clinical bacteria, at National and Regional Level.Vanaf1 jan 2018 → 31 dec 2018
Publicaties
1 - 10 van 22
- Acquired rifampicin resistance during first TB treatment: magnitude, relative importance, risk factors and keys to control in low-income settings(2022)
Auteurs: Armand Van Deun, Valentin Bola, Rossin Lebeke, Michel Kayomo Kaswa, Mohamed Anwar Hossain, Mourad Gumusboga, Gabriela Torrea, Bouke de Jong, Leen Rigouts, Tom Decroo
- Finding the right balance between efficacy and tolerability for TB treatment: the search continues(2021)
Auteurs: A.K.J. Maug, M.A. Hossain, Mourad Gumusboga, Tom Decroo, Wim Mulders, Sofie Braet, Jozefien Buyze, D A Jiménez, Céline Schurmans, Natacha Herssens, et al.
Pagina's: 84-86 - Mycobacterium tuberculosis borderline rpoB mutations: emerging from the unknown(2021)
Auteurs: Armand Van Deun, Tom Decroo, Kya Jai Maug Aung, Mohamed Anwar Hossain, Mourad Gumusboga, Pim De Rijk, Sabira Tahseen, Bouke de Jong, Leen Rigouts
- The simple direct slide method is comparable to indirect Lowenstein Jensen proportion culture for detecting rifampicin resistant tuberculosis(2021)
Auteurs: Beatrice Achan, Benon B. Asiimwe, Moses L Joloba, Mourad Gumusboga, Willy Ssengooba, Freddie Bwanga
- Bedaquiline can act as core drug in a standardized treatment regimen for fluoroquinolone-resistant rifampicin-resistant tuberculosis(2021)
Auteurs: Tom Decroo, Kya Jai, Kya Jai Maug Aung, Mohamed Anwar Hossain, Mourad Gumusboga, Nimer Ortuno-Gutierrez, Bouke C de Jong, Armand Van Deun
- Injectables' key role in rifampicin-resistant tuberculosis shorter treatment regimen outcomes(2020)
Auteurs: Tom Decroo, Aung Kya Jai Maug, Mohamed Anwar Hossain, Cécile Uwizeye, Mourad Gumusboga, Tine Demeulenaere, Nimer Ortuno-Gutierrez, Bouke de Jong, Armand Van Deun
- First-line tuberculosis treatment with double-dose rifampicin is well tolerated(2020)
Auteurs: A.K.J. Maug, M.A. Hossain, Mourad Gumusboga, Tom Decroo, Wim Mulders, Sofie Braet, Jozefien Buyze, Diana Arango, Céline Schurmans, Natacha Herssens, et al.
Pagina's: 499-505 - Management of multidrug-resistant tuberculosis with shorter treatment regimen in Niger: nationwide programmatic achievements(2020)
Auteurs: Alberto Piubello, Mahamadou Bassirou Souleymane, Souleymane Hassane-Harouna, Abdourahamane Yacouba, Pauline Lempens, Mourtala Mohamed Assao-Neino, Ibrahim Maman-Lawan, Sala Attaher, Boubacar Moustapha, Alphazazi Soumana, et al.
- Variable ability of rapid tests to detect Mycobacterium tuberculosis rpoB mutations conferring phenotypically occult rifampicin resistance(2019)
Auteurs: Armand Van Deun, Emmanuel André, Justine Kaisergruber, Willy Ssengooba, Christel Desmaretz, Siemon Gabriëls, Michèle Driesen, Maren Diels, Sylvie Asnong, Kristina Fissette, et al.
- Twenty years of rifampicin resistance surveillance in Bangladesh: periodic vs. continuous monitoring(2018)
Auteurs: A Van Deun, K.J.M. Aung, M.A. Hossain, M. A. H. Salim, Mourad Gumusboga, Bouke de Jong, Tom Decroo
Pagina's: 1450-1461